Cruinn Diagnostics acquires UK-based Katalyst Diagnostics, creating a €50m group and supporting plans to expand across the UK, Ireland and Europe.
Irish diagnostics supplier Cruinn Diagnostics has acquired UK-based Katalyst Diagnostics in a deal that marks its entry into the British market and advances its long-term growth strategy.
The acquisition strengthens Cruinn’s position in the diagnostics sector by adding Katalyst Diagnostics’ established NHS customer relationships, local commercial infrastructure and specialist point-of-care diagnostics portfolio. It also opens opportunities for cross-border growth, allowing Cruinn to introduce its products to UK healthcare customers while expanding Katalyst’s offerings in the Irish market.
The combined group now employs more than 100 people and generates annual revenues of more than €50 million. The business has set ambitious targets for further growth through a combination of organic expansion and additional acquisitions across Ireland and the UK.
KEY NUMBERS: Cruinn Diagnostics Expansion
- €150m revenue target over coming years
• €50m+ combined group revenues today
• 100+ employees across Ireland and the UK
• First UK acquisition for Cruinn Diagnostics
• Established NHS customer relationships added
• Mental health, oncology and paediatrics among key sectors served
• UK market identified as primary growth platform
• Further UK and Irish acquisitions planned
Editorial takeaway: The deal gives Cruinn immediate scale in the UK, creating a €50m-plus diagnostics group with ambitions to triple revenues through expansion and acquisitions.
Point-of-care revolution
Katalyst Diagnostics specialises in point-of-care diagnostic solutions used across a range of clinical settings, including mental health, oncology and paediatrics. The acquisition complements Cruinn’s existing laboratory diagnostics business and strengthens its growing presence in the point-of-care testing market.
The deal forms part of Cruinn’s strategy to build a larger diagnostics distribution group across Ireland and the UK. The company also intends to evaluate opportunities in selected continental European markets where acquisitions could provide additional scale, specialist expertise and market access.
👉 No tech background needed to bring your business into the AI age! Secure your Google AI Professional Certificate to complete the certification at no cost. Apply now and get started!
Peter Hussey, CEO of Cruinn Diagnostics, said: “Katalyst Diagnostics is a strong strategic fit for Cruinn and gives us a solid platform in the UK market from day one. The business brings established NHS customer relationships, local market knowledge and a differentiated point-of-care diagnostics portfolio that complements our existing capabilities. Together, we see a clear opportunity to support customers across Ireland and the UK with a broader range of diagnostic solutions, while building a larger and more diversified group.”
Hussey said the acquisition represents the beginning of a wider expansion programme for the company.
“This acquisition is an important first step in our UK buy-and-build strategy. Our ambition is to grow the Group to €150 million in revenue over the coming years by backing strong businesses, investing in people and infrastructure, and expanding the specialist innovative products and services we offer to customers.”
Katalyst Diagnostics will continue to operate under its existing leadership team, with Managing Director Afsheen Khan remaining in charge of the UK business.
Khan welcomed the transaction and said it would support the next phase of growth for the company.
“Cruinn is the right long-term partner for Katalyst Diagnostics. The Group understands our market, shares our focus on service and quality, and has the infrastructure to help us grow. I look forward to continuing to lead the UK business as part of the Cruinn Group and to bringing our portfolio to more customers and patients across the UK and Ireland.”
The transaction brings together two businesses with expertise in diagnostics distribution, clinical customer support and specialist product access. Cruinn believes the enlarged group is well positioned to expand its reach across healthcare markets in Ireland and the UK while pursuing further acquisition opportunities.
Image at top: John Hussey, CEO of Cruinn Diagnostics
FAQ: Cruinn Diagnostics’ Acquisition of Katalyst Diagnostics
Why has Cruinn Diagnostics acquired Katalyst Diagnostics?
Cruinn acquired Katalyst Diagnostics to establish an immediate presence in the UK market, expand its diagnostics portfolio and strengthen its position in point-of-care testing.
What does Katalyst Diagnostics do?
Katalyst Diagnostics supplies point-of-care diagnostic solutions used in healthcare settings including mental health, oncology, paediatrics and other specialist clinical services.
What will the combined business look like?
The enlarged group employs more than 100 people and generates annual revenues of more than €50 million.
Will Katalyst Diagnostics continue operating independently?
Yes. Katalyst Diagnostics will continue under its existing leadership team, with Afsheen Khan remaining as Managing Director.
How does the acquisition strengthen Cruinn’s business?
The deal adds NHS customer relationships, UK commercial infrastructure, local market expertise and a complementary diagnostics portfolio.
What are Cruinn’s growth ambitions?
Cruinn aims to grow group revenues to €150 million over the coming years through organic growth and further acquisitions.
Will there be more acquisitions?
Yes. Cruinn has outlined a buy-and-build strategy focused on further acquisition opportunities in both Ireland and the UK.
What opportunities does the deal create for customers?
The acquisition broadens access to diagnostic solutions across Ireland and the UK while expanding the range of products and services available to healthcare providers.
Is Cruinn considering expansion beyond Ireland and the UK?
Yes. The group plans to assess selected opportunities in continental Europe where acquisitions could provide additional scale and market access.
What sectors will benefit most from the combined group’s expertise?
Laboratory diagnostics, point-of-care testing, NHS healthcare services and specialist clinical settings including oncology, paediatrics and mental health.
In summary: The acquisition gives Cruinn an immediate UK platform, expands its customer base and supports an ambitious strategy to build a €150 million diagnostics group through further investment and acquisitions.
👉 No tech background needed to bring your business into the AI age! Secure your Google AI Professional Certificate to complete the certification at no cost. Apply now and get started!
-
Bank of Ireland is welcoming new customers every day – funding investments, working capital and expansions across multiple sectors. To learn more, click here
-
For support in challenging times, click here
-
Listen to the ThinkBusiness Podcast for business insights and inspiration. All episodes are here. You can also listen to the Podcast on:
-
Spotify
-
SoundCloud
-
Apple
